Zealand Pharma A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zealand Pharma A/S
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
Following ABL Bio’s sizable Parkinson’s disease drug deal with Sanofi early this year, Korean bioventure Kainos Medicine is under the spotlight as its novel PD drug candidate enters Phase II in the US.
The small-cap biotech is not currently favored by investors but CEO Anat Cohen-Dayag tells Scrip she believes Compugen could have the optimal TIGIT strategy.
French AI-driven drug design firm will employ multiple technology platforms in latest tie-ups. Apellis looks to augment Empaveli-led portfolio in C3 complement R&D alliance with Affilogic.
- Other Names / Subsidiaries
- Encycle Therapeutics, Inc.
- Valeritas Holdings, Inc.